SCHEMBL432595

SCHEMBL432595

NC(=O)OC(Cl)C(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6600516 0.97 LMNA (0.33)
SCHEMBL10621774 0.78
SCHEMBL22556151 0.75 LMNA (0.37)
SCHEMBL7769672 0.75
SCHEMBL2760916 0.75 LMNA (0.32)
SCHEMBL583308 0.73
SCHEMBL3024 0.73
SCHEMBL28966811 0.72
SCHEMBL1865097 0.71
SCHEMBL1269148 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9770514-B2 Tamper-resistant pharmaceutical dosage forms ExxPharma Therapeutics LLC (US) 2017-09-26 US claimed
US-20150064250-A1 Tamper-Resistant Pharmaceutical Dosage Forms ExxPharma Therapeutics LLC (US) 2015-03-05 US claimed
US-20130224211-A1 GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-08-29 US claimed
WO-2012027555-A2 GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-03-01 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-20260138946-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB CURIA SPAIN S A U (ES) 2026-05-21 US disclosed
US-20260062395-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES CURIA SPAIN S A U (ES) 2026-03-05 US disclosed
US-12552746-B2 Process and intermediates for the preparation of upadacitinib CURIA SPAIN, S.A.U. (ES) 2026-02-17 US disclosed
EP-4313156-B1 DISULFIDE-BASED PRODRUG COMPOUNDS UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2025-08-06 EP disclosed
EP-4565571-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES CURIA SPAIN, S.A.U. (ES) 2025-06-11 EP disclosed
CN-115151529-B Processes and intermediates for preparing Wu Pati n 库里亚西班牙公司 2025-04-22 CN disclosed
CN-119768395-A Processes and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives 库里亚西班牙公司 2025-04-04 CN disclosed
US-4959360-A α-adrenergic receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1990-09-25 US disclosed
US-4957914-A ANTIDEPRESSANTS, ANXIOLYTICS, HYPOTENSIVE AGENTS SYNTEX (U.S.A.) INC. (US) 1990-09-18 US disclosed
EP-0366122-A2 Demethylepipodophyllotoxin derivatives WARNER-LAMBERT COMPANY (US) 1990-05-02 EP disclosed
WO-1989012054-A1 alpha-ADRENERGIC RECEPTOR ANTAGONISTS SMITHKLINE BECKMAN CORPORATION (US) 1989-12-14 WO disclosed
WO-1989012050-A1 alpha-ADRENERGIC RECEPTOR ANTAGONISTS SMITHKLINE BECKMAN CORPORATION (US) 1989-12-14 WO disclosed
EP-0344979-A2 Alfa-adrenergic receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1989-12-06 EP disclosed
EP-0344980-A2 Alpha-adrenergic receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1989-12-06 EP disclosed